The QualityStocks Daily Wednesday, August 15th, 2018

Today's Top 3 StockMarketWatch

PoliticsAndMyPortfolio (SQZZF) +66.58%

MarketBeat (GWGH) +34.26%

StockMarketWatch (CGC) +30.42%

The QualityStocks Daily Stock List

BTCS, Inc. (BTCS)

RedChip, PennyPro, Stock Commander, HotStockProfits, Value Penny Stocks, Money Morning, 1-2-3 Stock Alerts, Fortune Stock Alerts, Penny Stock Circle, StockMarketQuote.us, StockMister, SmallCapVoice, AddictivePennyStocks, Bullseyestox.com, PennyStockRumors.net, PennyStocks Forever, PricelessPenny, and TheMicrocapNews reported on BTCS, Inc. (BTCS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BTCS, Inc. is a blockchain technology focused company headquartered in Silver Spring, Maryland. The Company is an early entrant in the Digital Asset market. In addition, it is one of the first U.S. publicly traded companies engaged with Digital Assets and blockchain technologies. Blockchains are distributed public ledgers, which can fundamentally influence all industries around the world that require trust and rely on or use record keeping. The Company has a record of accomplishment of accurate digital asset trend prediction. BTCS’ shares trade on the OTC Markets Group’s OTCQB.

BTCS’ plan (subject to additional financing) is to create a portfolio of digital assets, such as bitcoin and other "protocol tokens", to provide investors a diversified pure-play exposure to the bitcoin and blockchain industries. The Company’s intention is to acquire digital assets by way of open market purchases; and participating in initial digital asset offerings (or initial coin offerings).

Furthermore, BTCS may acquire digital assets through resuming its transaction verification services business (or mining) via outsourced data centers and earning rewards in digital assets by securing their respective blockchains. Moreover, the Company is concentrating on growth via acquisition.

A blockchain is secured and maintained by a network of specialized servers (nodes) globally. All transactions are publicly available on a blockchain. Transactions undergo verification and confirmation through nodes worldwide before being added to a blockchain.

Last month, BTCS announced the appointment of Mr. Jonathon R. Read to its Board of Directors. Mr. Read has held many executive positions with domestic and global companies over a career, which spans more than 35 years. Most recently, from 2013 to the present, he has served as Managing Partner of Quadratam1 LLC (Scottsdale, Arizona) a firm specializing in providing financial and organizational consulting services for growth-stage companies in the United States and China.

Before that, Mr. Read served as Chief Executive Officer (CEO) or President of Timefire VR, Inc., previously known as EnergyTek Corp. During his tenure, he repositioned, re-financed, and merged the company into an entity centered on the virtual reality sector.

Mr. Charles Allen, BTCS CEO, said, "Jonathon brings a wealth of public company expertise to our board. As we move forward on our plans to build a vertically-integrated operation in the burgeoning blockchain space, Jonathon's experience should add tremendous value."

BTCS, Inc. (BTCS), closed Wednesday's trading session at $0.0478, up 0.63%, on 1,558,264 volume with 177 trades. The average volume for the last 60 days is 1,862,947 and the stock's 52-week low/high is $0.04/$0.3849.

chart

HedgePath Pharmaceuticals, Inc. (HPPI)

BUYINS.NET, MarketWatch, InvestorsHub, and Stockhouse reported earlier on HedgePath Pharmaceuticals, Inc. (HPPI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It discovers, develops, and plans to commercialize leading-edge therapeutics for patients with cancer. The Company is looking to repurpose the Food and Drug Administration (FDA) approved antifungal pharmaceutical itraconazole as a potential treatment for cancer. HedgePath Pharmaceuticals is headquartered in Tampa, Florida.

HedgePath is the exclusive U.S. licensee of a patented formulation of itraconazole, named SUBA-Itraconazole. Clinical studies have shown it to have more bioavailability than generic itraconazole. The Hedgehog signaling pathway is a significant regulator of cellular processes in vertebrates. This includes cell differentiation, tissue polarity, as well as cell proliferation.

HedgePath Pharmaceuticals believes (based on published research) that inhibiting the Hedgehog pathway could delay or possibly prevent the development of certain cancers in humans. Leveraging research undertaken by key investigators in the field, the Company’s plan is to explore the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization.

The design of “SUBA technology” (which stands for “super bioavailability”) is to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma. It has improved absorption and substantially reduced variability in comparison to generic itraconazole.

In July of 2017, HedgePath Pharmaceuticals announced that the FDA provided further guidance concerning the Company’s continuing, open-label Phase 2(b) clinical trial studying the effect of SUBA-Itraconazole (SUBA-Cap) oral capsules in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. BCCNS results from a genetic mutation that causes the Hedgehog pathway (a major regulator of processes in cells) to function improperly, leading to the chronic formation of basal cell tumors.

The FDA's guidance came in the form of a written response by the FDA to HedgePath Pharmaceuticals’ Type-C meeting background package.  Such a meeting is a standard element of the regulatory review process leading to a potential New Drug Application (NDA) to the FDA.

This past October, HedgePath Pharmaceuticals announced that it completed enrolment in its earlier announced open label, Phase 2(b) SCORING clinical trial, testing SUBA™-Itraconazole in patients with BCCNS (Basal Cell Carcinoma Nevus Syndrome - or Gorlin Syndrome).

Recently, HedgePath Pharmaceuticals announced that it entered into a definitive preferred stock and warrant Securities Purchase Agreement with its majority stockholder Mayne Pharma.

Mayne Pharma agreed to invest up to $5 million in HedgePath Pharmaceuticals, the first $2.4 million of which was received by the Company on January 10, 2018, with a second tranche of $1.6 million to be funded by mid-2018, and a third tranche to be funded by year end if HedgePath Pharmaceuticals’ pending New Drug Application (NDA) for the SUBA-Itraconazole treatment of Basal Cell Carcinoma Nevus Syndrome (BCCNS) is accepted for filing by the FDA.

HedgePath Pharmaceuticals, Inc. (HPPI), closed Wednesday's trading session at $0.30, up 5.26%, on 13,122 volume with 7 trades. The average volume for the last 60 days is 17,200 and the stock's 52-week low/high is $0.1923/$0.42.

chart

LexaGene Holdings, Inc. (LXXGF)

MarketWatch, Stockhouse, Capital Cube, Barchart, Pinnacle Digest, Stockwatch, YCharts, MetalsNews.com, The Street, OTC Markets, Dividend Investor, Insider Financial, Investor Place, Financial Trends, and Markets Insider reported on LexaGene Holdings, Inc. (LXXGF), and today we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

A biotechnology company listed on the OTCQB, LexaGene Holdings, Inc. develops instrumentation for pathogen detection. It is developing the LX6, which is the very first fully automated pathogen detection platform that is open-access.  This open-access feature will enable end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. LexaGene Holdings has its corporate headquarters in Beverly, Massachusetts.

Earlier this month, LexaGene announced that it considerably expanded its operations in Massachusetts. The Company recently signed a lease for a 17,500-square-foot space, located at 500 Cummings Center, Suite 4550, in Beverly.

LexaGene Holdings is working to change the pathogen detection landscape through providing a customizable sample-to-answer instrument, which is more rapid and sensitive than anything presently available. It is working to transform the way pathogen testing is performed by multi-billion dollar industries. These industries include food safety, veterinary diagnostics, water quality management, aquaculture farming, and more.

LexaGene Holdings has strategic relationships with Boston Engineering – a development partner; as well as the Lawrence Livermore National Laboratory. The Company’s Microfluidic Technology is open access - users can load standard pathogen specific assays onto the instrument for customized testing.

A feature of this technology is extreme sensitivity. The flow-through instrument processes huge sample volumes to maximize the chances of detecting ultra-rare pathogens. The Microfluidic Technology features low cost per test and it is also user-friendly.

At the end of November 2017, LexaGene announced that it completed the assembly of its prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform. This technology will be able to screen for up to 22 pathogens at once and deliver results in one hour. The design of the technology is also to be used by people with no knowledge of automated instrumentation, microbiology, or molecular biology.

Yesterday, LexaGene Holdings announced that the TSX Venture Exchange ranked the Company in its 2018 TSX Venture 50. This is a yearly ranking of top performing companies on the Exchange.

Dr. Jack Regan, LexaGene Holdings’ Chief Executive Officer, said, “Being recognized as a top 50 company for the Exchange reflects the rapid growth we’ve experienced in 2017 and great support from the investment community. Following our recent completion of the assembly of our prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform, LexaGene is poised to make a powerful impact for industries interested in pathogen detection – from food safety to veterinary diagnostics.”

LexaGene Holdings, Inc. (LXXGF), closed Wednesday's trading session at $0.60, down 1.28%, on 8,796 volume with 13 trades. The average volume for the last 60 days is 52,892 and the stock's 52-week low/high is $0.5775/$1.285.

chart

Table Trac, Inc. (TBTC)

NetworkNewsWire, Penny Stock Tweets, MarketWatch, OTC Markets, Wallet Investor, Stockhouse, BUYINS.NET, Marketbeat, FeedBlitz, Market Exclusive, M2 Communications and Investors Hangout reported on Table Trac, Inc. (TBTC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Table Trac, Inc. is a developer and provider of casino information and management systems. These systems automate and monitor the operations of casinos. The Company has systems installed in North America, South America, Central America, and the Caribbean. OTCQB-listed, Table Trac is headquartered in Minnetonka, Minnesota. It also has a South America office in Envigado, Colombia.

The TableTrac™ table games management system is a patented solution. TableTrac™ provides table games managers and gaming operators with all the modules needed to manage and run a table games Pit. These include modules from credit fills and reporting to patron management and promotions.

The CasinoTrac™ casino management system provides a complete set of all the modules necessary to ensure floor operations, real-time floor monitoring, daily revenue auditing, and managerial accounting and players club operations for any size casino.

The design of Table Trac’s KioskTrac™ is to reward play and increase visitation. KioskTrac™ provides operators with a vehicle to drive revenues. This is from “text-to-win” and campaigns, to email and direct mail.

In 2017, Table Trac signed 13 new customer contracts. The Company delivered its first systems in Maryland and Nevada. At the end of 2017, Table Trac had casino management systems, table games management systems and ancillary products installed with continuing support and maintenance contracts with 86 casino operators in greater than 130 casinos around the world.

The Sauk Suiattle C.C. of Washington, who are opening their first casino, recently selected Table Trac's CasinoTrac system to be their casino management system of choice.

Mr. Chad Hoehne, Table Trac’s President, said, "I am very pleased to be partnering with the Sauk Suiattle C.C and am very happy to have them join our casino system customers.  We are dedicated to making our system easy to use and easy to own, with a commitment to service and value."

Yesterday, Table Trac announced financial results for the quarter ending June 30, 2018. The Company delivered five systems during the quarter. Revenues increased from $2,183,787 in 2017 to $3,003,135 in 2018.

Gross Margin for Q2 of 2018 was $1,196,531 versus $753,931 in 2017. Net Income for 2018 was $410,538 versus Net Income of $164,988 for 2017.

Table Trac, Inc. (TBTC), closed Wednesday's trading session at $2.70, up 8.00%, on 11,067 volume with 25 trades. The average volume for the last 60 days is 1,382 and the stock's 52-week low/high is $1.45/$3.00.

chart

Ecosphere Technologies, Inc. (ESPH)

Buzz Stocks, Penny Pick Finders, PennyStockProphet, SmallCapVoice, Wall Street Resources, TheMicrocapNews, PennyStocks24, Planet Penny Stocks, SecretStockPromo, and StockOnion reported previously on Ecosphere Technologies, Inc. (ESPH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Ecosphere Technologies, Inc. is a development and Intellectual Property (IP) licensing company. It develops environmental solutions for worldwide water, energy, industrial, and agricultural markets. The Company helps industry boost production, reduce costs, and protect the environment through a portfolio of unique, patented technologies and exclusive and nonexclusive licensing opportunities across a broad array of industries and applications globally. Ecosphere Technologies is headquartered in Stuart, Florida.

Ecosphere has an extensive portfolio of patented clean technologies. These can be purchased and licensed for use in large-scale and sustainable applications across industries, nations, as well as ecosystems. The Company’s technologies include the Ecos PowerCube®, the Ecos GrowCube™, and Ozonix®.

The Ecosphere technologies and products are available by way of numerous brands and subsidiaries. These include Sea of Green Systems, Ecosphere Development Company, and Fidelity National Environmental Solutions. Ecosphere’s objective is to help clean energy producers’ gain more control over their water resources, quality, and completion costs through providing effective mobile water recycling solutions.

The Ecosphere Ozonix® Technology provides a chemical-free alternative to high-volume water recycling for a diverse range of applications. These range from the oil & natural gas industry and mining to agriculture and municipal wastewater treatment.

The Ecos GrowCube® is a state-of-the-art, turn-key, fully-automated "greenhouse". It employs hydroponic growing techniques to maximize the amount of crop production possible in a given footprint. The Ecos GrowCube® incorporates the Company’s patented Ozonix® water treatment technology.

The Ecos PowerCube® is the world’s largest, mobile, solar-powered generator. It runs on high power photovoltaic panels. These panels extend from its container combined with an easy to set up wind turbine. Energy is stored in onboard batteries.

Furthermore, Ecosphere has its Ozonix Sentinel. This is the world's first line of water treatment vessels for cleaning up endangered rivers and lakes.

Sea of Green Systems’ (SOGS) sublicensee in the agricultural industry, Gulf Coast Organics (GCO), signed an agreement with Wedgworth's, Inc., to be the exclusive distributor in Florida for its Amp Agronomy™ plant nutritional line. Wedgworth's provides custom blended agricultural plant nutrient products across Florida to help farms grow and prosper. CAVISONIX®, developed by SOGS and Ecosphere Technologies, uses ultrasonic cavitation to treat fertilizers for increased plant availability.

Wedgworth's is recognized as Florida's largest custom fertilizer dealer since 1932. Sea of Green Systems, Inc. (SOGS) is a subsidiary of Ecosphere Technologies. SOGS develops proprietary equipment, lighting and fertilizer solutions for the Precision Agriculture industry.

Ecosphere Technologies, Inc. (ESPH), closed Wednesday's trading session at $0.011, up 10.00%, on 6,580 volume with 2 trades. The average volume for the last 60 days is 88,599 and the stock's 52-week low/high is $0.004/$0.033.

chart

Thunder Energies Corporation (TNRG)

The Stock Radio, Marketbeat, WalletInvestor, InvestorPlace, The Silicon Review, InvestorsHub, The Street, Stockwatch and Market Exclusive reported on Thunder Energies Corporation (TNRG), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Thunder Energies Corporation centers on the manufacture, sale, and service of varied technologies in the United States. The Company formerly went by the name Thunder Fusion Corporation. It changed its name to Thunder Energies Corporation in May of 2014. OTCQB-listed, Thunder Energies is based in Tarpon Springs, Florida.

The Company markets its technologies via three divisions. These are Nuclear Instruments, Optical Instruments, and Combustion Equipment. Concerning the Division of Nuclear Equipment, the production, promotion, sale and service of the Santilli Thermal Neutron Source is based on a novel synthesis of the neutron from a hydrogen gas (global patent pending).

Regarding the Division of Optical Equipment, its focus is the production, promotion, sale and service of pairs of Galileo telescopes with convex lenses to detect matter-galaxies & Santilli telescopes with concave lenses to detect antimatter-galaxies (global patent pending).

Pertaining to the Division of Combustion Equipment, its emphasis is the production, promotion, sale and service of the novel HyperFurnace that achieves the complete combustion of fossil fuels and an enhanced energy output (patented and global patents pending).

Dr. Ruggero M. Santilli, Chief Executive Officer and Chief Scientist of Thunder Energies announced this past May new advances for the model of Directional Neutron Source developed in the U.S. and tested in nuclear facilities in Europe for the detection in airports of nuclear material, which may be concealed in suitcases, the detection and concentration of precious metals in mining operations, different military uses, and other applications.

In July, Mr. Brian Buckley, Operations Manager of Thunder Energies, announced that Dr. Ruggero M. Santilli was traveling in Europe to visit clients and promote additional sales of the Directional Neutron Source.

Mr. Buckley stated in July, "This visit to Italy, Czech Republic, and Hungary is most productive because it allows Dr. Santilli to supervise the installation and commissioning of the Directional Neutron Source sold to Europe. In addition, this visit provides a timely opportunity to expand the European market with sales to new clients."

Yesterday, Dr. Ruggero M. Santilli announced an invited presentation of Thunder Energies’ new HyperCombustion at the International Conference on Pure and Applied Mathematics (icpam 2018) Eotvos Lorand University, Budapest, Hungary, July 10 to 14, 2018.

Dr. Santilli stated: "… At the international conference icpam 2018, I announced the development, subject to proper funding, of the Company's new HyperCombustion(TM) whose aim is to achieve full combustion of fossil fuels resulting in the alleviation of environmental problems and an increase of energy output.”

Thunder Energies Corporation (TNRG), closed Wednesday's trading session at $0.01, down 9.09%, on 506,500 volume with 8 trades. The average volume for the last 60 days is 544,164 and the stock's 52-week low/high is $0.0085/$0.30.

chart

NioCorp Developments Ltd. (NIOBF)

Savvy Trader Resource, InvestorsHub, Stockhouse, StreetInsider, Morningstar, Proactive Investors, Equity Clock, MarketWatch, 4-Traders, InvestorIntel, Junior Mining Network, and Simply Wall St reported on NioCorp Developments Ltd. (NIOBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NioCorp Developments Ltd. is a developer of superalloy metals and is developing a superalloy materials project in Southeast Nebraska. The Project will produce Niobium, Scandium, and Titanium. The Company formerly went by the name Quantum Rare Earth Developments Corp. It changed its corporate name to NioCorp Developments Ltd. in March 2013. OTCQX-listed, NioCorp is headquartered in Centennial, Colorado.

Niobium is used to produce superalloys and high strength, low alloy steel. Scandium is a superalloy material that can be combined with aluminum to make alloys with increased strength and improved corrosion resistance. Titanium is used in varied superalloys.

NioCorp Developments is developing North America's only niobium/scandium/ titanium project. The Elk Creek Project is the highest-grade niobium project in North America, and the largest prospective producer of scandium worldwide. The Elk Creek Project is positioned near Elk Creek, Nebraska.

The Elk Creek Feasibility Study (FS) shows anticipated production of 7,055 tonnes per annum (tpa) of Ferroniobium, 103 tpa of Scandium Trioxide, and 11,445 tpa of Titanium Dioxide over its 32-year operating life.

The estimation is that the Elk Creek Project will have pre-tax Net Present Value (NPV) of US$2.3 billion, with a pre-tax Internal Rate of Return (IRR) of 24.3 percent, and to produce gross Life Of Mine (LOM) Revenue of $17.6 billion, with Operating Margin of $12.2 billion. The economics were calculated using an 8 percent discount rate.

In July, NioCorp noted that a U.S. Senate Committee chose to highlight NioCorp Developments’ Elk Creek Critical Minerals Project due to the uniqueness of the critical minerals it plans to make and because of the Project’s success in lessening its expected environmental impacts.

NioCorp testified in July in Washington, D.C. at a hearing of the U.S. Senate Energy and Natural Resources Committee.  The hearing examined the topic of “critical minerals” and opportunities to strengthen U.S. mineral security.

Mr. Mark A. Smith, NioCorp Developments’ Chief Executive Officer and Executive Chair of NioCorp, said he was pleased that the Company was selected from among hundreds of companies and projects to testify at the hearing.

Mr. Smith said, “We are very gratified that the Energy and Natural Resources Committee chose to highlight the Elk Creek, Nebraska Critical Minerals Project. The Committee had hundreds of options from which to choose in terms of which companies and projects to highlight at a hearing like this.  I believe they chose NioCorp and the Elk Creek Project because of the many highly unique aspects of this project, including the multiple critical minerals we will produce, the fact that we will produce only critical minerals, and because the many environmental advances the Project has been able to achieve.”

NioCorp Developments Ltd. (NIOBF), closed Wednesday's trading session at $0.51033, down 4.22%, on 32,034 volume with 26 trades. The average volume for the last 60 days is 112,901 and the stock's 52-week low/high is $0.293/$0.621.

chart

Energy Services of America Corp. (ESOA)

MicroCap Spotlight, OTC Markets, TradingView, Market Exclusive, Dividend Investor, Streetwise Reports, Capital Cube, Wallet Investor, GuruFocus, MarketWatch, Marketbeat, 4-Traders, Stockhouse, Barchart, and Real Pennies reported on Energy Services of America Corp. (ESOA), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Energy Services of America Corp. provides contracting services for energy related companies. At present, it primarily serves the gas, petroleum, power, chemical, and automotive industries. Nonetheless, it does some other incidental work including water and sewer projects. Energy Services of America is the parent company of C.J. Hughes Construction Company and Nitro Electric Company. Energy Services of America has its head office in Huntington, West Virginia.

The Company constructs, but does not own, natural gas pipelines for its customers that are part of interstate and intrastate pipeline systems, which move natural gas from producing areas to consumption areas. Energy Services of America also constructs and replaces gas line services to individual customers of the different utility companies. Most of its customers are in West Virginia, Virginia, Ohio, Pennsylvania, and Kentucky.

Regarding the oil industry, Energy Services of America provides an array of services relating to pipeline, storage facilities, and plant work. For the power, chemical, and automotive industries, the Company provides a total range of electrical and mechanical installations and repairs. This includes substation and switchyard services, site preparation, equipment setting, pipe fabrication and installation, packaged buildings, transformers, and other ancillary work in regard to these. 

Concerning the gas industry, Energy Services of America mainly engages in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It engages in the construction of interstate and intrastate pipelines, with a concentration on intrastate pipelines.

The Company’s other services include liquid pipeline construction, pump station construction, production facility construction, and water and sewer pipeline installations. Other services additionally include diverse maintenance and repair services and other services related to pipeline construction.

In January 2018, Energy Services of America, parent company of C.J. Hughes Construction Company, Inc., announced the hiring of Mr. Jimmy Johnson by C.J. Hughes to assist its business development and marketing efforts in the Utica and Marcellus Shale areas.  Mr. Johnson has almost three decades of sales and management experience in diverse industries. The last six years he has centered on sales and consulting in the natural gas industry.

Yesterday, Energy Services of America announced the filing of its quarterly report on Form 10-Q for the quarter ended June 30, 2018.  The Company earned Revenues of $29.5 million and $85.2 million for the three and nine months ended June 30, 2018, respectively.

Net Income Available to Common Shareholders was $1.0 million and $65,000 for the three and nine months ended June 30, 2018, respectively.  The Company had Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $2.7 million ($0.19 per share) and $3.9 million ($0.27 per share) for the three and nine months ended June 30, 2018, respectively.

Energy Services of America Corp. (ESOA), closed Wednesday's trading session at $1.16, up 5.45%, on 14,100 volume with 23 trades. The average volume for the last 60 days is 6,478 and the stock's 52-week low/high is $0.536/$1.17.

chart

IronClad Encryption Corporation (IRNC)

InvestorsHub, OTC Markets, YCharts, Barchart, Investors Hangout, Stock News Now, TradingView, The Street, Simply Wall St, MarketWatch, 4-Traders, and PennyStockHub reported on IronClad Encryption Corporation (IRNC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

IronClad Encryption Corporation is a next-generation cyber defense company based in Houston, Texas. Its strategic and tactical data protection solutions strengthen existing encryption methods. The Company’s technology can provide continuous authentication of encrypted data transmitted, creating much stronger defenses to most hacker attacks. IronClad Encryption’s shares trade on the OTC Markets’ OTCQB.

IronClad Encryption-powered solutions use the Company’s patented Dynamic Encryption and Perpetual Authentication technologies to make all known key-based encryption technologies almost impossible to compromise. Dynamic Encryption Technology eliminates vulnerabilities caused by exposure of any single encryption key through continually changing encryption keys and keeping the keys synchronized in a fault-tolerant way.

Dynamic Encryption technology eliminates the single point of failure problem inherent in single-key encryption techniques. IronClad’s key management system continuously produces synchronous keys between the sender and receiver. Each key is assigned to a small amount of data. Therefore, if a hacker were to access one of hundreds of millions of keys, the amount of data he would obtain would be almost useless.

IronClad Encryption offers its ICEMicro. This is the world’s first context-free and natively-secure container. It enables all developers to take ownership of application data security. Using ICEMicro, any developer can secure communication between containers across varied scheduling and orchestration platforms, IaaS services, transport-layer security protocols, and on-premises or hybrid environments utilizing Docker-compatible hypervisors. ICEMicro gives DevOps teams a way to build, install, and run secure applications without the costs associated with legacy security strategies.

IronClad Encryption has partnered with Black Pearl Engineering Management, Inc. to co-develop ultra-secure products based on IronClad’s patented ultra-secure cybersecurity algorithms and methodologies. The joint venture (JV) operates under the name "Black ICE". It is first focusing on network gateway products.

The Black ICE Programmable Logic Control (PLC) / Network Gateway product line specifically targets the Industrial Control System security market. The new product line is an intelligent management system. It will integrate IronClad Encryption’s patented ultra-secure algorithms and methodologies in a package, which can be easily and seamlessly integrated into an existing infrastructure.

BlackICE Barrier is the first product in a family of BlackICE products. BlackICE Barrier is specifically targeted at enterprises and industrial use cases where data and control systems require the highest level of security.

Regarding the Company’s solutions, IronClad Encryption provides fine-grain access control. As such, customers can put "rings" around a desktop computer, laptop, or server to control data access. For instance, a team of people operating within a ring could be authorized to view documents but not allowed to download or transfer those documents. Moreover, the rings support multifactor authentication. In addition, they can be used to enforce multiparty authorization by 2 to 64 parties.

IronClad Encryption Corporation (IRNC), closed Wednesday's trading session at $0.30, down 33.33%, on 7,815 volume with 6 trades. The average volume for the last 60 days is 5,111 and the stock's 52-week low/high is $0.05/$12.00.

chart

WRIT Media Group, Inc. (WRIT)

SeriousTraders, Tip.us, Real Pennies, StocksToBuyNow, Pennystockmania, Great Penny Picks, and SmallCapVoice reported earlier on WRIT Media Group, Inc. (WRIT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

WRIT Media Group, Inc. is a diversified media and software business whose shares trade on the OTC Markets. The Company’s portfolio of wholly-owned businesses includes Front Row Networks; Amiga Games; Retro Infinity, Inc.; and Pandora Venture Capital. WRIT Media Group is headquartered in Los Angeles, California.

WRIT Media’s operations include digital currency software development, including trading platforms and Blockchain solutions, content production and distribution; and video game distribution by way of mobile platforms. Its Front Row Networks produces and distributes live event programming for international digital broadcast to movie theaters and online streaming.

WRIT’s Amiga Games is a software company. Amiga is restarting the Amiga brand through publishing retro video games on smartphones and tablets. WRIT’s Retro Infinity is a video game distribution site. It publishes video games from Amiga, Atari and other "retro" brands on contemporary smartphones, tablets and consoles.

Additionally, WRIT’s Pandora Venture Capital is a financial technology company. Pandora has an emphasis on its digital currency, Pelecoin, a new generation of digital currency, Blockchain technology solutions, and also the CrypFXPro trading platform. WRIT Media's proprietary CrypStock digital trading platform will provide the technology that will support the creation and trading platform for Pelecoin and other digital currencies.

WRIT Media Group plans to integrate its Pelecoin Blockchain technology into products and applications that can be used to make it as easy to spend digital currencies, cryptocurrencies, and Pelecoin, as it is to spend US Dollars. Through the Company’s acquisition of Pandora Venture Capital, WRIT assumed a skilled management team with backgrounds in payments, telecom, and digital currency.

Last week, WRIT Media Group announced a number of technology innovations within its Pelecoin cryptocurrency system. The Company plans over the next year to enhance its software platform through adding more features and by expanding its ecosystem through new products.

During the past several months, WRIT Media's development team has built the core functionality of its digital currency system. The Company now offers a new feature that enables users to mine four cryptocurrencies at the same time by employing Pelecoin's proprietary mining algorithm software. The core system is complete. The foundation is ready for Pelecoin to expand and become a strong platform suitable for broader adoption, with updated core features and extensive new ones for its ecosystem.

WRIT Media Group, Inc. (WRIT), closed Wednesday's trading session at $0.075, up 7.14%, on 47,001 volume with 10 trades. The average volume for the last 60 days is 20,602 and the stock's 52-week low/high is $0.038/$0.56.

chart

Foothills Exploration, Inc. (FTXP)

MarketWired, OTC Markets, and InvestorsHub reported on Foothills Exploration, Inc. (FTXP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Foothills Exploration, Inc., through its wholly-owned subsidiary, Foothills Petroleum, Inc. (a Nevada corporation), is an early stage independent oil and gas exploration and production company. It involves in the acquisition and development of oil and gas properties in the Rockies. The Company’s goal is to acquire dislocated and underdeveloped oil and gas assets and maximize those assets.  Foothills Exploration is headquartered in Denver, Colorado.

The Company’s strategy is to build a balanced portfolio of E&P assets through concentrating on acquiring producing and developmental properties in the Rockies and focusing on the generation of high-impact oil and gas exploration projects. Foothills Exploration’s goal is to build a land bank of more than 200,000 acres of proven, probable, and prospective reserves.

Currently, Foothills Exploration holds 41,181 acres in the Greater Green River Basin in Wyoming. Its Springs Prospect consists of 38,120 contiguous acres. This is a multiple objective oil resource play in the Greater Green River Basin.

Moreover, the Company has a 35 percent Working Interest (WI) in the Ladysmith Anticline prospect. This prospect is in Fremont County, Wyoming. Ladysmith Anticline in entirety amounts to 3,061 acres. Its location is between the Great Divide/Greater Green River Basin and the Wind River Basin.

Foothills also has its PawPaw Project. The Pawpaw project is a 3-D seismic defined prospect. It covers 4,467 acres and is a direct analog to the highly productive Tensleep Formation “Enigma” Field positioned two miles south.

The Company also has its Ironwood Project. The Ironwood Project is a 6,115-acre up dip field extension play. The adjacent “Cotton Creek” Field produced about 67 million barrels of oil (MMBO) and 68 billion cubic feet of gas (BCFG), chiefly from the Phosphoria Formation.

Foothills Exploration announced in February 2017 that since acquiring Tiger Energy Partners International on December 30, 2016, Foothills has successfully reworked two wells in its Duck Creek project obtaining production from the Green River formation.

Regarding the Duck Creek Area – Natural Buttes Field, Foothills Exploration plans to re-enter two wells in September in the Duck Creek region situated in Uintah County, Utah, in the Natural Buttes field. The Duck Creek wells recently had a third-party engineering report completed. The Report calculated a total PV-10 value of $707,000 of Proved Developed Producing and Proved Developed Non-Producing reserves.

Concerning the Altamont- Bluebell and Brundage Canyon areas, a third-party reserve report was conducted on certain properties, which were acquired via the Tiger Energy Partners International acquisition. According to this Report, the properties have roughly 5.4 million barrels of Proved Undeveloped Reserves. The well depths range from 5,500 feet in the Brundage Canyon area to roughly 18,000 feet in the Altamont-Bluebell area.

Foothills Exploration, Inc. (FTXP), closed Wednesday's trading session at $0.13, up 7.44%, on 5,000 volume with 1 trade. The average volume for the last 60 days is 4,741 and the stock's 52-week low/high is $0.10/$0.61.

chart

Noble Roman’s, Inc. (NROM)

TaglichBrothers, Marketbeat, FeedBlitz, The Bowser Report, StockOodles, Wall Street Resources, and SmallCapVoice reported on Noble Roman’s, Inc. (NROM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Noble Roman's, Inc. sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations. The Company’s business model consists of three growth venues. These are Grocery Take-n-Bake Licensing; Non-Traditional Franchising; and Stand-Alone Franchising. OTCQB-listed, Noble Roman’s has its corporate office in Indianapolis, Indiana.

The Company franchises and licenses under the Noble Roman’s Pizza, Noble Roman’s Take-N-Bake, Tuscano’s Italian Style Subs, and Noble Roman's Craft Pizza & Pub (CPP) trade names.  Noble Roman’s has awarded franchise and/or license agreements in all 50 U.S. States plus Washington, D.C. In addition, it has awarded franchise and/or license agreements in Canada, Puerto Rico, the Bahamas, Italy, and the Dominican Republic.

Concerning Stand-Alone Venues, these are traditional pizzeria locations and Take-n-Bake locations. There is a merging over time between the kinds of Stand-Alone Venues: Live Yeast Dough; Hand-Rolled Breadsticks; and Baking Services.

Grocery Take-n-Bake Licensing involves licensing to sell Noble Roman’s Pizza. This is a component program using Noble Roman’s ingredients, in which delis assemble pizzas from standard Noble Roman’s ingredients.

Regarding Non-Traditional Venues, these are usually located in a host facility whose principal business is other than foodservice. These facilities can add pizza-focused foodservice as a Revenue Center; as a Facility Draw; and as an Employee Benefit.

The first Noble Roman's Craft Pizza & Pub (CPP) opened on January 31, 2017 in Westfield, Indiana in the Monon Marketplace on Main Street/Highway 32 across from Grand Park.

This past May, Noble Roman's announced it opened a fourth location of its new-generation, stand-alone pizzeria concept, Noble Roman's Craft Pizza & Pub. The newest location is in Carmel, Indiana on Main Street just east of Meridian Street/US 31N.

Last week, Noble Roman's announced it awarded a franchise to Patrick and Holly O'Neil for a location in Tippecanoe County that includes Lafayette and West Lafayette, Indiana. The O'Neil's are experienced multi-unit foodservice operators and Dairy Queen's largest franchisee in Indiana, with 19 locations in Indiana.

During the three-month and six-month periods ended June 30, 2018, Total Revenue from Noble Roman’s four company-owned and operated Craft Pizza & Pub  locations were $1.2 million and $2.4 million, respectively. Total Expenses for the Craft Pizza & Pub locations for the three-month and six-month periods ended June 30, 2018 were $964,000 and $1.8 million, for an operating profit of 22.6 percent and 22.4 percent for the three-month and six-month periods.

Noble Roman’s, Inc. (NROM), closed Wednesday's trading session at $0.65, down 5.80%, on 55,100 volume with 18 trades. The average volume for the last 60 days is 13,021 and the stock's 52-week low/high is $0.38/$0.87.

chart

Kiwa Bio-Tech Products Group Corporation (KWBT)

SmallCapVoice, Lions of Wall Street, Fast Moving Stocks, Darth Trader, The Stock Psycho, Wallstreetlivechat, Penny Stock Rumble, StockMister, The Penny Play, Equities, Top Gun and OTC Picks reported previously on Kiwa Bio-Tech Products Group Corporation (KWBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kiwa Bio-Tech Products Group Corporation is a manufacturer focusing on eco-friendly bio-based fertilizers promoting soil health. The Company develops, manufactures, distributes, and markets novel, cost-effective and environmentally safe bio-technological products for agricultural and environmental conservation. Organic, ecologically sound, and "green" practices are the Company’s theme. Kiwa Bio-Tech Products Group has its head office in Claremont, California.

The Company’s dedication is to eco-agricultural development and environmental control through developing, producing, and selling bio-technological products with high technology, low-cost, and high productivity to satisfy increasing market demand. Kiwa Bio-Tech’s commitment is to making safe food, further developing eco-agriculture, and upholding a responsibility of contributing to China's agricultural safety, food safety, and a healthy lifestyle.

The design of Kiwa Bio-Tech’s products is to enhance the quality of human life through increasing the value, quality, and productivity of crops and lessening the negative environmental impact of chemicals and other wastes. The Company uses new bio-technological skills at its core.

Kiwa Bio-Tech’s new products structure includes 16 types of products in 5 major categories. These categories are Biological Organic Fertilizer, Compound Microorganism Fertilizer, Microorganism Bacterium Agent, Biological Soluble Fertilizer, and Organic-Inorganic Compound Fertilizer.

Kiwa Bio-Tech has a strategic cooperation agreement with the Beijing Zhongpin Agricultural Science and Technology Development Center (Zhongpin Center). Zhongpin Center is the Chinese Agricultural Science and Technology Innovation and Development Committee's executive implementation agency (called the Agricultural Science and Technology Commission).

Via the guidance and support by the Zhongpin Center, Kiwa Bio-Tech will participate and be involved in China's National Soil Remediation Program and the building of the National Ecological Security Agriculture Industrial Chain Standardization System's operation and process.

Kiwa Bio-Tech launched a joint venture (JV) with Zhongshi'an Agricultural Science & Technology Co., Ltd. and Xintaitianyi Financial Service and Science & Technology Co., Ltd. The name of the JV is Inner Mongolia Jingnong Investment Management Co. Ltd.

As of May 15, 2018, Kiwa Bio-Tech has established four retail outlet stores in Shaanxi Province, which distribute its fertilizer products.

Recently, Kiwa Bio-Tech signed a non-exclusive contract granting distribution rights to Hainan Yunong Eco-agricultural Science and Technology Co., Ltd. This contract calls for the delivery of more than 7,000 tons of microbial fertilizer products. The kinds of products included in the transaction include biological organic fertilizers, compound microbial fertilizers, as well as Yimuling water-soluble fertilizers.

Today, Kiwa Bio-Tech announced its financial results for the three months ended June 30, 2018. Record Quarterly Revenue for Q2 2018 is $5,334,830. Record Quarterly Gross Profit for Q2 2018 is $1,461,328.

Kiwa Bio-Tech Products Group Corporation (KWBT), closed Wednesday's trading session at $1.01, down 0.98%, on 1,054 volume with 3 trades. The average volume for the last 60 days is 3,327 and the stock's 52-week low/high is $0.91/$2.50.

chart

Agritek Holdings, Inc. (AGTK)

CFN Media Group, Promotion Stock Secrets, PennyPro, SmallCapVoice, and Cannabis Financial Network News reported on Agritek Holdings, Inc. (AGTK), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Formed in 2010, Agritek Holdings, Inc. is a fully integrated, active cannabis real estate investor and branding consultant in the legal cannabis sector. The Company provides innovative technology and agricultural solutions for the medicinal and recreational cannabis industry. Currently, Agritek owns property in Colorado approved for cultivation, and manufacturing capabilities through California partnerships. It also owns a number of Hemp and cannabis brands for distribution including "Hemp Pops" and "California Premiums". Agritek Holdings is headquartered in Miami, Florida. The Company has a satellite office in San Juan, Puerto Rico

Agritek does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act. It does not intend to do so in the future. The Company’s solution is an integrated platform designed for commercialization in three high-value segments of the global cannabis market – Real Estate, AGTK Brands/IP, and Infrastructure.

Agritek’s Colorado property is 80-Acres approved for cannabis cultivation or manufacturing facility in Pueblo, Colorado. Its Puerto Rico property is a 25,000-sq. ft. licensed cannabis cultivation and manufacturing facility. Agritek’s Canada property is a cannabis friendly "Bud & Breakfast" concept. It is one 1-hour from Quebec City. It is on 15-acres that includes nine guest rooms plus a separate detached grow facility.

Agritek’s brands are a premium positioned set of consumer brands for medical wellness and recreational use. Agritek owns a number of hemp and cannabis brands for distribution. These include MD Vapes, MicroDose Strips, and the above-mentioned "Hemp Pops" and "California Premiums."

Agritek Holdings announced this past April that it completed, and fully executed, a five-year operational and exclusive licensing agreement with a 25,000-sq. ft. and one of the largest approved cultivation facilities in San Juan, Puerto Rico. The Company will be the exclusive funding source, and supervise all infrastructure buildout, equipment lease/finance, security systems and personnel and provide access of experienced Colorado and California cultivation crews to ensure the facility meets all standard operating procedures as set forth by the Department of Health of Puerto Rico.

With the five-year operational contract and licensing agreement, Agritek will receive revenue in the form of property rent, licensing fees on all vaporizer and edible brands, equipment and lighting rental and financing fees along with equity interest in the property.

Also, in May, Agritek Holdings announced that it executed a land purchase agreement to purchase a "420 Style" resort and estate property about one hour outside of Quebec City, Quebec. This 15-acre estate comprises nine innovative guest suites and horse stables. It is within walking distance to a public golf course that the Company will have ownership in for guests staying at the resort. A separate structure will serve as a small grow facility run by patient employees and caretakers on the property that may be toured by guests of the facility.

This month, Agritek Holdings announced that Phase One of construction is commencing this month at the 1919 Clinic's 25,000 square foot cultivation and manufacturing facility located in San Juan, Puerto Rico. Agritek will provide funding for the build out of the operation, extraction and all equipment, and cultivation experts under the Agritek team via its executed five-year Operations and Licensing Agreement with 1919 Clinic.

Last week, Agritek Holdings announced its initial orders from its' state licensed manufacturer for its brand "MicroDose" Oral Strips or "MD Strips" for the medicinal market of California. First orders and samples are being sent to dispensaries and local delivery services in San Diego and Orange County this month. Agritek will provide the licensing and packaging to produce the exclusive line of 10 mg and 50 mg oral strips as a medicinal alternative for patients.

Agritek Holdings, Inc. (AGTK), closed Wednesday's trading session at $0.0097, up 8.26%, on 4,241,056 volume with 85 trades. The average volume for the last 60 days is 2,949,084 and the stock's 52-week low/high is $0.0088/$0.0545.

chart

The QualityStocks Company Corner

Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC Pink: NUGS) announces the signing of a definitive agreement to acquire the Fitamins CBD brand. Under the terms of the agreement, Fitamins will be distributing their vitamin and hemp derived CBD formulations through their network of 600+ wholesalers catered to the Asian-American market. Also today, CannabisNewsWire released a report on the company detailing how Cannabis Strategic Ventures this morning announced that its wholly-owned subsidiary, Pure Applied Sciences, has commenced production of its Halo Filters. To view the full press release, visit: http://cnw.fm/5g7pN. Additionally, NUGS was featured in an article on how the cannabidiol (CBD) market has arguably been cannabis’ best success to date, as CBD-based products continue to work their way into society in a variety of forms, ranging from health and beauty products to pet applications.

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.69, up 9.74%, on 43,320 volume with 123 trades. The average volume for the last 60 days is 24,433 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

chart

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD”) and Phivida Holdings Inc. (CSE: VIDA) (OTC.PHVAF) ("Phivida") are pleased to announce the signing of a final definitive joint venture agreement (“Agreement”) to develop and operate Cannabis Beverages Inc. (“CanBev”) at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario.

Headquartered in Vancouver, Canada, with operations offices in southern California, Phivida Holdings Inc. (CSE: VIDA) (OTCQX: OTCQX) is a premium food and beverage company that develops CBD-infused functional foods, beverages and supplements poised for global distribution. All products in the Phivida label are infused with organic, hemp-derived cannabinoids into a variety of premium foods, beverages and clinical products for everyday health. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s motto – “Celebrating Health and Wellness, in Harmony™” – underscores Phivida’s mission to lead the alternative health care sector as the benchmark standard in premium CBD-infused functional beverages and tinctures. To execute this goal, Phivida is taking advantage of positive legislative developments in the United States and has defined an elevated national route-to-market strategy across the U.S. where small regional distributors will be now be replaced with large national distributors.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who as Phivida’s chief commercial officer is tasked with driving new sales revenue growth.

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF), the company’s strong balance sheet carries CAD$15.7 million with no debt or loans with less than 60 million shares outstanding and the company is now well-capitalized to fun major mainstream distribution with a solid structure poised for long-term growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

Encapsulated CBD is infused into functional beverages, food and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health and wellness conditions. Phivida tests every product for microbials, heavy metals, pesticides, residual solvents, terpenes, and potency to guarantee less than 0.3 percent THC (tetrahydrocannabinol, the chemical compound in cannabis responsible for a euphoric high) is present.

Regulations

Federally legal under the 2014 Farm Bill, CBD from Hemp Oil is a rapid growth market across the USA. When derived from marijuana, CBD remains a schedule one controlled substances, giving hemp derived CBD oil infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the USA Industrial Hemp laws to an agricultural commodity status and effectively removed hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the US CBD-Hemp sector. In February 2018, the Supreme Court preceded over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp, and the legality of industrial hemp. In the final ruling the Supreme Court unequivocally determined that – when produced domestically under the Farm Bill – hemp (and its derivatives) are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA) giving the Farm Bill primary jurisdiction over the governance of the CBD-Hemp Oil industry in the USA.

The DEA further conceded it does not “seek to control cannabinoids,” and that only marijuana derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g. US Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreation cannabis – with edibles to be added in 2019. The bill will officially become law as of October 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

3 Wholly Owned Subsidiaries

  • Phivida Organics Inc. offers professional-grade, wholesale, whole plant hemp oil extracts made from 100-percent certified organic hemp stalk. Phivida’s hemp oil extracts are CO2-extracted under quality assurance/clinical standards and are third-party lab tested to assure only pharmaceutical grade, cGMP certified, full-spectrum products are produced and available for sale. Phivida Organics produces hemp oil extracts that deliver nano-encapsulated cannabinoids in water soluble formulations designed to be absorbed up to 10 times faster than other oils, providing up to 400 percent bioavailability. Phivida Hemp Oil Vida+ extract products are available now online at www.Phivida.com.
  • Phivida Nutrition blends the best of nature into CBD-infused lifestyle branded beverages including a variety of CBD infused iced teas and CBD infused flavored waters.
  • Phivida Enhanced – Under the VIDA brand, CBD-infused tinctures, capsules and other supplement products are distributed to alternative health care clinics across the USA.

WeedMD-Phivida

Phivida has signed a binding letter of intent to joint venture WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on cannabis-infused beverages. The new joint-venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario, Canada. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets.

Management from both WeedMD and Phivida are collaborating on design and engineering strategies and site evaluations on a 610,000-square-foot, state-of-the art facility in Strathroy for the development of CanBev. As an emerging certified food grade production plant, the Strathroy facility is an ideal location and comes is equipped with extensive production infrastructure, including 50,000 sq. ft. of food production and packaging area, cold storage, loading docks, and adequate space to expand for future growth.

Strategic Agreements

Phivida Organics has also entered into an agreement to carry out a pharmacokinetic (PK) study on its hemp-derived, nanoencapsulated CBD with Artelo Biosciences Inc. at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England. The study will test encapsulated-CBD on healthy volunteers and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations developed by Phivida Organics.

Phivida has also activated distribution agreements with Asayake Inc. to become one of the first federally approved CBD-infused food and supplement brands in Japan. With first mover status achieved, Phivida now markets to an underserved, yet highly informed population of 127 million patients and practitioners. The supplement market in Japan is estimated at US$10 billion with the overall functional foods market at US$21 billion. The Asia-Pacific region is the fastest growing market for natural plant-based supplements. Phivida now plans to prepare a formal application to Japan’s Consumer Affairs Agency to register the company’s CBD-infused functional food and beverage products for approval under the country’s Food with Functional Claims regime. The functional beverage market in Japan is estimated at US$10.35 billion with a CAGR of 2.5 percent (2015-2025).

Further Information

www.Phivida.com
+1 (844) 744-6646 (ext. #2)
IR@Phivida.com

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.538, up 7.60%, on 20,870 volume with 26 trades. The average volume for the last 60 days is 26,914 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018. These filings are available for review on the Company's SEDAR profile at www.sedar.com.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.1205, up 7.87%, on 346,599 volume with 807 trades. The average volume for the last 60 days is 245,005 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

chart

WhereverTV Broadcasting Corp. (OTCQB: TVTV)

The QualityStocks Daily Newsletter would like to spotlight WhereverTV Broadcasting Corp. (TVTV).

WhereverTV (OTCQB:TVTV), (the “Company”) announced CEO, Edward D. Ciofani’s return interview with Everett Jolly, host of Uptick Newswire’s “Stock Day” Podcast.

WhereverTV Broadcasting Corp. (OTC: TVTV) is a next-generation OTT (Over-the-top) television subscription service that manages live-stream broadcast programming rights across multiple devices, geographies and languages, providing viewers with personalized service that is truly “wherever” they may be watching TV.

WhereverTV’s patented Interactive Program Guide (IPG) technology currently handles over 125 live channels that are broadcasted securely over the Internet to any Internet-enabled device anywhere in the world. Many of the company’s channels are the same as those broadcasted by traditional cable and satellite companies. For example, the World News Now package includes One America News, RT News (Russia Today), Bloomberg TV, CBN News and EuroNews Live — the latter provides pan-European coverage in 350 million households in 155 countries. Other channel packages include Choice TV (a wide variety of popular options for the family), Spanish TV, Faith TV and Morocco TV, providing current genre-specific subscriptions for news, faith, drama, sports, movie, reality and children’s programming.

WhereverTV’s free app works with iOS and Android devices to cover the spectrum of mobile consumer needs, as well as with personal desktop or laptop computers through its over the top (OTT) platform. The platform delivers channels, shows and events to SmartTVs and digital media receivers that include Google Chromecast, AppleTV, Amazon Fire TV, iPhone, iPad, Android Smartphone and TabletPCs, with DVR recording functionality slated for future development.

The company, based in Fort Myers, Florida, was developed in 2007 as a solution to its founder’s frustration with the complexities of trying to stream English speaking content while abroad.  As the live-streaming market has developed over the decade since then, WhereverTV has gained recognition as a pioneer in next-generation content delivery systems.

WhereverTV’s strategy is to increase revenue-generating subscriptions worldwide through the acquisition of content that is desirable to consumers and deliverable anywhere a device can connect to the Internet. Prepaid accounts will be accessed through the cloud, and the IPG technology will allow users to make their viewing choices. The company has developed two separate divisions, one for worldwide distribution and one for Latin American distribution.

In 2017, the company acquired Digital Rodeo, LLC, a Tennessee limited liability company that delivers a rich mixture of music and videos from independent country artists, current arrests and legacy artists, as well as similar Florida-based companies Digital RodeoTV, LLC (Name changed to WhereverTV Country in 2018), Digital CrossTV, Inc., Digital PopTV, Inc., and Digital RockTV, Inc.

WhereverTV is transitioning from a development to operational company and in doing so we have refined our 2018 business model,” CEO Edward D. Ciofani stated. “Our business model calls for content acquisition from around the world, exclusive content development, Major Marketing Alliances, similar to the announced Google Chromecast for Latin America and major marketing initiatives including social media marketing. … There are a lot of content providers (channel providers) around the world that offer a uniquely diversified perspective of cultures, travel and lifestyle content.”

As an increasing number of people “Cord-Cutters” no longer subscribe to the traditional cable or satellite distribution but rather a simpler lower cost means of watching content. The streaming OTT industry is expected to grow to $62 billion by 2020 — nearly triple its revenues in 2015, per Goldman Small Cap Research. Future Market Insights estimated the North America OTT market alone at $16.29 billion in 2017 with a CAGR of 17.4 percent through 2028. The arrival of 5G technology this year has the potential to accelerate the pace.

WhereverTV Broadcasting Corp. (TVTV), closed the day's trading session at $0.0732, up 4.57%, on 14,290 volume with 4 trades. The average volume for the last 60 days is 34,020 and the stock's 52-week low/high is $0.041/$0.46.

Recent News

chart

Zenosense, Inc. (OTCQB: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

MIDS Cardiac™, a handheld diagnostic device for cardiac emergency triage being developed by Zenosense, Inc. (OTCQB: ZENO), could prove to be revolutionary in the diagnostic process. Incorporating the patented MIDS technology, which is predicated on the nano-magnetic detection of assay beads and has demonstrated detection of low enough assay bead numbers to be suitable for high sensitivity cardiac biomarker tests, shows real potential to be able to ensure accurate results, delivered at a fraction of the time required by large and expensive laboratory analyzers and right at the point of care, according to an article by Zacks Small Cap Research (http://nnw.fm/u0w7A) and recent quantitative results released by Zenosense.

Zenosense, Inc. (OTCQB: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.38, up 4.11%, on 131,262 volume with 31 trades. The average volume for the last 60 days is 259,664 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

chart

Sharing Services, Inc. (OTC: SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services, Inc. (OTC: SHRV) has appointed network marketing veteran Keith Halls to the positions of president and COO of its Elepreneur, LLC subsidiary. Moving forward, he will be tasked with leading the company’s global growth (http://nnw.fm/3RcZp). SHRV has also appointed Global Payroll Gateway (GPG) as its payment processor and e-commerce financial partner (http://nnw.fm/ciXS5). That company is seen as an important asset as SHRV expands internationally.

Sharing Services, Inc. (OTC: SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders –  Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.34, up 3.03%, on 23,758 volume with 9 trades. The average volume for the last 60 days is 20,630 and the stock's 52-week low/high is $0.125/$0.95.

Recent News

chart

CytoDyn Inc. (OTCQB: CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications in the treatment of HIV, cancer, and inflammatory conditions, announces that Michael A. Klump, President and Chief Executive Officer of Argonne Capital Group, has joined the CytoDyn Board of Directors. Mr. Klump is a significant investor in CytoDyn and brings extensive financing and mergers and acquisition expertise to the CytoDyn Board.

CytoDyn Inc. (OTCQB: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.5011, up 2.27%, on 249,089 volume with 38 trades. The average volume for the last 60 days is 330,329 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is the developer of a disruptive drug delivery platform, DehydraTECH™, that the company out-licenses to entities aiming to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. To view the full article, visit: http://nnw.fm/rAx5Q. Also today, NetworkNewsWire released a report on the company detailing how LXRP is one of the companies looking at alternative solutions to the scientifically established harmful health effects of smoking, using fatty acids to make a pleasing, fast, effective delivery system for nicotine and cannabidiol (CBD).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.74, up 2.96%, on 259,563 volume with 297 trades. The average volume for the last 60 days is 229,867 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

chart

Auscrete Corp. (OTC: ASCK)

The QualityStocks Daily Newsletter would like to spotlight Auscrete Corp. (ASCK).

In a world that’s keenly aware of the impact that every action has on the environment, businesses in all types of industries are committing to operate as sustainably as possible. Auscrete Corp. (OTC: ASCK) offers a unique path to environmental responsibility and economic efficiency. The building materials manufacturing company is focused on leading the way in the “green” movement.

Auscrete Corp. (OTC: ASCK) is a building products manufacturer of environmentally-friendly, energy-efficient housing and commercial structures using a lightweight hybrid concrete material developed through a proprietary technology. Auscrete’s unique process produces a medium that is cost-efficient, extremely soundproof, offers high insulation values, requires very low maintenance, won’t burn, non-toxic, highly resistant to insects and mold, and resists damage from hurricane forces and earth tremors. It’s a more affordable, energy-efficient “green” construction material that can be utilized for building residential housing and commercial structures.

Affordable homes are increasingly becoming more difficult to purchase in the U.S. with the median price of a new home consistently rising while wages stay stagnant in many areas and mortgage rates rise. The average price of new homes sold in the U.S. in 2017 was nearly $385,000, according to Statista. The homeownership rate in the U.S. has been in decline since 2004, the report states, and now amounts to a little more than 64 percent of Americans.

Auscrete’s lightweight concrete product is described as an aerated concrete material following infusion of a specially designed foaming agent during manufacture. This technology enables the product to have millions of minuscule air bubble “aggregates” introduced and evenly distributed throughout the cast sections, which creates a unique, lightweight product without compromising strength or structural integrity. Each hybrid panel also incorporates a distinctive XPS insulation amalgamation that guarantees greater comfort in a wide range of climatic conditions and a reduction in heating and cooling costs. The final product is a light and strong concrete panel with an extremely high insulation value, as well as excellent fire resistance and sound-proofing qualities.

Auscrete’s product also offers a high strength-to-weight ratio, allowing architects and engineers to develop new design and construction concepts that take advantage of the product’s reduced weight, which is nearly half that of normal concrete. Each panel can be cast in large sections, a common size being 16-feet by 8-feet, for easier transportation and faster construction on site. Savings are enhanced, not only by the energy efficiency of each panel, but through the use of mass production techniques. Auscrete estimates the company can produce a ready-to-move-in turnkey house for around $100 per square foot, which is significantly less than the 2017 median list price of $148 per square foot in the U.S., according to a report by Zillow.

Auscrete is constructing its flagship, 10-acre facility in Goldendale, Washington, on initially 5 acres the company recently purchased with the option to purchase another 5 adjacent acres. This new campus will ultimately comprise of 6 buildings, including 3 production buildings of 25,000 sq. ft. with each production buildings’ capacity of 100 homes annually, giving this flagship facility the ability to produce 300 homes or equivalent commercial structures per year.

During this construction phase, Auscrete has leased a commercial building in Goldendale. The facility will be used as a temporary headquarters and will also serve as a refurbishing station for production equipment the company has developed and used in its prior production plant. John Sprovieri, CEO and founder of Auscrete Corporation, is at the helm of the company with Mike Young serving as vice president of internal operations and Otto Paulette controlling the in-house mechanical services.

Auscrete’s Investor Relations Director, Lee Odom said, “The company’s construction process has already attracted interest from many developers, contractors and builders, some with large tracts of land looking to make available, significant numbers of Affordable Homes throughout the Country. Additionally, there have been significant commercial projects offered including 300 room destination hotel resorts, correctional facilities, a shopping complex, and a court house along with a flood of inquiries from people who are looking for more affordable building options”.

“This could really launch the commercial aspect for?ASCK, apart from residential home production which so many investors are not yet aware of,” Odom said. “A strong combination of both will lead?ASCK?to better performance through all business cycles, thus continuing to enhance the shareholder values, which is always the ultimate goal of Auscrete Corporation.”

Auscrete Corp. (ASCK), closed the day's trading session at $0.0508, up 0.20%, on 21,800 volume with 3 trades. The average volume for the last 60 days is 121,289,728 and the stock's 52-week low/high is $0.0001/$0.10.

Recent News

chart

Global Payout, Inc. (OTC: GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) is pleased to announce that it has successfully signed and begun implementing one of San Diego’s premier dispensaries, The Healing Center (THC), and is expected to go live with MTrac by the end of the week.

Global Payout, Inc. (OTC: GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.01152, off by 1.54%, on 4,611,674 volume with 116 trades. The average volume for the last 60 days is 5,182,145 and the stock's 52-week low/high is $0.0099/$0.16.

Recent News

chart

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields; medical devices; and research and development, today shares it has initiated the up-listing process through the OTCQB in anticipation of approval of its Form 10 Registration Statement. Also today, CannabisNewsWire released a report on the company detailing how ETST is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://cnw.fm/9tTZ1). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://cnw.fm/ej7NG).

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.70, off by 8.38%, on 10,041 volume with 12 trades. The average volume for the last 60 days is 10,296 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

chart

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada approved natural health products (the "Products").

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0271, off by 6.55%, on 191,778 volume with 27 trades. The average volume for the last 60 days is 613,769 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

chart

DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), and Asterion Cannabis Inc. ("Asterion") announce that they have signed an agreement (the "Licensing Agreement"), whereby Asterion has granted to PreveCeutical a worldwide licence to use, manufacture, distribute and sell three Health Canada approved natural health products (the "Products").

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.41, off by 14.58%, on 2,808,950 volume with 3,554 trades. The average volume for the last 60 days is 1,912,418 and the stock's 52-week low/high is $0.4205/$5.95.

Recent News

chart

Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF)

The QualityStocks Daily Newsletter would like to spotlight Hiku Brands Co. Ltd. (DJACF).

Headquartered in British Columbia’s picturesque Okanagan Valley, Hiku Brands Co. Ltd. (CSE: HIKU) (OTC: DJACF) iis a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. Hiku’s wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. Hiku’s Dominion Facility is a state-of-the-art ACMPR licensed production facility capable of producing approximately 660 kg year of dried cannabis flower. Hiku’s second facility, a 22,580 sq ft warehouse, “the FUTURE LAB”, is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, Hiku’s annual production capacity is expected to be in excess of 5,000 kgs. Hiku was founded by the proven entrepreneurial team that started SAXX Underwear®.

On December 21, 2017, Hiku and TS Brandco Holdings Inc. (“Tokyo Smoke”) announced that they have entered into a binding Letter of Intent (“LOI”) to merger the two companies and create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the merger will use the name “Hiku Brands Company Ltd.” (“Hiku”) to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku recently closed on a $10 million strategic equity investment from Aphria Inc. (“Aphria”) (TSX:APH and US OTC: APHQF) to expand their product offering ahead of the recreational market.

Upon completion of the merger, Hiku will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named “Brand of the Year” at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku Brands Co. Ltd. (DJACF), closed the day's trading session at $1.473, up 30.41%, on 747,092 volume with 566 trades. The average volume for the last 60 days is 248,471 and the stock's 52-week low/high is $0.20/$3.8799.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.